PLUS THERAPEUTICS INC (PSTV) Stock Price, Quote, News and Overview
NASDAQ:PSTV - Nasdaq - US72941H5090 - Common Stock - Currency: USD
PSTV Quote, Performance and Key Statistics
0.3175
-0.02 (-5.22%)
The current stock price of PSTV is 0.3175 USD. In the past month the price decreased by -59.66%. In the past year, price decreased by -85.16%.
PSTV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18 | 327.00B | ||
| AMGN | AMGEN INC | 13.25 | 147.86B | ||
| GILD | GILEAD SCIENCES INC | 14.1 | 135.84B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.87 | 66.38B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.94B | ||
| ARGX | ARGENX SE - ADR | 98.52 | 35.31B | ||
| ONC | BEIGENE LTD-ADR | 5.9 | 25.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.45B | ||
| NTRA | NATERA INC | N/A | 21.01B | ||
| BIIB | BIOGEN INC | 8.25 | 19.13B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.11B |
Related stock screener links
About PSTV
Company Profile
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in Austin, Texas and currently employs 21 full-time employees. The company went IPO on 2000-08-09. The firm is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Company Info
PLUS THERAPEUTICS INC
4200 Marathon Blvd., Suite 200
Austin TEXAS 78756 US
CEO: Marc. H. Hedrick
Employees: 21
Phone: 17372557194
PLUS THERAPEUTICS INC / PSTV FAQ
What is the stock price of PLUS THERAPEUTICS INC today?
The current stock price of PSTV is 0.3175 USD. The price decreased by -5.22% in the last trading session.
What is the ticker symbol for PLUS THERAPEUTICS INC stock?
The exchange symbol of PLUS THERAPEUTICS INC is PSTV and it is listed on the Nasdaq exchange.
On which exchange is PSTV stock listed?
PSTV stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PLUS THERAPEUTICS INC stock?
10 analysts have analysed PSTV and the average price target is 9.82 USD. This implies a price increase of 2992.13% is expected in the next year compared to the current price of 0.3175. Check the PLUS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PLUS THERAPEUTICS INC worth?
PLUS THERAPEUTICS INC (PSTV) has a market capitalization of 5.40M USD. This makes PSTV a Nano Cap stock.
How many employees does PLUS THERAPEUTICS INC have?
PLUS THERAPEUTICS INC (PSTV) currently has 21 employees.
What are the support and resistance levels for PLUS THERAPEUTICS INC (PSTV) stock?
PLUS THERAPEUTICS INC (PSTV) has a resistance level at 0.57. Check the full technical report for a detailed analysis of PSTV support and resistance levels.
Is PLUS THERAPEUTICS INC (PSTV) expected to grow?
The Revenue of PLUS THERAPEUTICS INC (PSTV) is expected to grow by 19.43% in the next year. Check the estimates tab for more information on the PSTV EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PLUS THERAPEUTICS INC (PSTV) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PSTV, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PSTV, evaluating the profitability, health, valuation and growth aspects
- PLUS THERAPEUTICS INC (PSTV) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PLUS THERAPEUTICS INC (PSTV) Sales and EPS estimates to see what analysts future expectations are.
- PLUS THERAPEUTICS INC (PSTV) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PLUS THERAPEUTICS INC (PSTV) Insider and Institutional Ownership to learn about the owners and their transactions.
- PLUS THERAPEUTICS INC (PSTV) Stock Chart to make your own analysis
- PLUS THERAPEUTICS INC (PSTV) Latest news and press-releases to stay up to date.
Does PLUS THERAPEUTICS INC (PSTV) stock pay dividends?
PSTV does not pay a dividend.
When does PLUS THERAPEUTICS INC (PSTV) report earnings?
PLUS THERAPEUTICS INC (PSTV) will report earnings on 2025-08-12, after the market close.
What is the Price/Earnings (PE) ratio of PLUS THERAPEUTICS INC (PSTV)?
PLUS THERAPEUTICS INC (PSTV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.17).
What is the Short Interest ratio of PLUS THERAPEUTICS INC (PSTV) stock?
The outstanding short interest for PLUS THERAPEUTICS INC (PSTV) is 13.51% of its float. Check the ownership tab for more information on the PSTV short interest.
PSTV Technical Analysis
PSTV Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PSTV. Both the profitability and financial health of PSTV have multiple concerns.
PSTV Financial Highlights
Over the last trailing twelve months PSTV reported a non-GAAP Earnings per Share(EPS) of -2.17. The EPS increased by 52.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -195.66% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PSTV Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to PSTV. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 59.93% and a revenue growth 19.43% for PSTV